Of the two pathways described, notably PI3K/AKT and MAPK pathways, it has always been the former that is frequently linked with HER2-positive breast cancer, especially during the early stages of the cancers, whereas MAPK activation and its activities occur more often in the metastatic setting or in cancers resistant to treatment (17). Here, ERBB2 is linked to breast cancer.